Volume 9, Issue 4 pp. 122-125

Cerebral protection in traumatic brain injury

Yat-Hang Tse,

Corresponding Author

Yat-Hang Tse

Division of Neurosurgery, Department of Surgery, University of Hong Kong, Queen Mary Hospital, Hong Kong SAR.

*Author to whom all correspondence should be addressed.
Email: [email protected]Search for more papers by this author

Gilberto Ka-Kit Leung,

Gilberto Ka-Kit Leung

Division of Neurosurgery, Department of Surgery, University of Hong Kong, Queen Mary Hospital, Hong Kong SAR.

Search for more papers by this author

Yiu-Wah Fan,

Yiu-Wah Fan

Division of Neurosurgery, Department of Surgery, University of Hong Kong, Queen Mary Hospital, Hong Kong SAR.

Search for more papers by this author

Yat-Hang Tse,

Corresponding Author

Yat-Hang Tse

Division of Neurosurgery, Department of Surgery, University of Hong Kong, Queen Mary Hospital, Hong Kong SAR.

*Author to whom all correspondence should be addressed.
Email: [email protected]Search for more papers by this author

Gilberto Ka-Kit Leung,

Gilberto Ka-Kit Leung

Division of Neurosurgery, Department of Surgery, University of Hong Kong, Queen Mary Hospital, Hong Kong SAR.

Search for more papers by this author

Yiu-Wah Fan,

Yiu-Wah Fan

Division of Neurosurgery, Department of Surgery, University of Hong Kong, Queen Mary Hospital, Hong Kong SAR.

Search for more papers by this author

First published: 26 October 2005

https://doi.org/10.1111/j.1744-1633.2005.00271.x

Citations: 8

Share a link

Email
Wechat
Bluesky

Abstract

With advances in the understanding of the pathophysiology of traumatic brain injury, many novel cerebroprotective measures have been developed. Many of them have undergone preclinical trials and have shown promising results, but the results have not translated into clinical benefits. Evidence of these cerebroprotective measures including NMDA-receptor antagonist, steroids, free radial scavengers, nimodipine, ziconotide, bradykinin receptor antagonist and dexanabinol has been reviewed. Problems encountered in clinical studies of traumatic brain injury are mainly related to the heterogenicity of traumatic brain injury and the design of clinical studies. Given all these difficulties, clear benefit of these measures cannot be shown and an optimum treatment strategy has yet been developed.

References

1 Tolias CM, Bullock MR. Critical appraisal of neuroprotection trials in head injury: what have we learned? Neurorx 2004; 1: 71–9.
10.1602/neurorx.1.1.71
PubMed Google Scholar
2 Narayan RK, Michel ME, Ansell B et al. Clinical trials in head injury. J. Neurotrauma 2002; 19: 503–57.
10.1089/089771502753754037
PubMed Web of Science® Google Scholar
3 Morris GF, Bullock R, Marshall SB, Marmarou A, Maas A, Marshall LF. Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two phase III clinical trials. The Selfotel Investigators. J. Neurosurg. 1999; 91: 737–43.
10.3171/jns.1999.91.5.0737
CAS PubMed Web of Science® Google Scholar
4 Alderson P, Roberts I. Corticosteroids for acute traumatic brain injury. Cochrane Database Syst. Rev. 2005; (1): CD000196.
10.1002/14651858.CD000196.pub2
PubMed Web of Science® Google Scholar
5 Marshall LF, Maas AI, Marshall SB et al. A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury. J. Neurosurg. 1998; 89: 519–25.
10.3171/jns.1998.89.4.0519
CAS PubMed Web of Science® Google Scholar
6 Darlington CL. Dexanabinol: a novel cannabinoid with neuroprotective properties. IDrugs 2003; 6: 976–9.
PubMed Web of Science® Google Scholar
7 Shohami E, Gallily R, Mechoulam R, Bass R, Ben Hur T. Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J. Neuroimmunol. 1997; 72: 169–77.
10.1016/S0165-5728(96)00181-6
CAS PubMed Web of Science® Google Scholar
8 Teasdale G, Bailey I, Bell A et al. A randomized trial of nimodipine in severe head injury: HIT I. British/Finnish Co-operative Head Injury Trial Group. J. Neurotrauma 1992; 9 (Suppl. 2): S545–S550.
PubMed Web of Science® Google Scholar
9 The European Study Group on Nimodipine in Severe Head Injury. A multicenter trial of the efficacy of nimodipine on outcome after severe head injury. J. Neurosurg. 1994; 80: 797–804.
10.3171/jns.1994.80.5.0797
PubMed Web of Science® Google Scholar
10 Murray GD, Teasdale GM, Schmitz H. Nimodipine in traumatic subarachnoid haemorrhage: a re-analysis of the HIT I and HIT II trials. Acta Neurochir. (Wien) 1996; 138: 1163–7.
10.1007/BF01809745
CAS PubMed Web of Science® Google Scholar
11 Bullock MR, Lyeth BG, Muizelaar JP. Current status of neuroprotection trials for traumatic brain injury: lessons from animal models and clinical studies. Neurosurgery 1999; 45: 207–17.
10.1097/00006123-199908000-00001
CAS PubMed Web of Science® Google Scholar
12 Marmarou A, Nichols J, Burgess J et al. Effects of the bradykinin antagonist Bradycor (deltibant, CP-1027) in severe traumatic brain injury: results of a multi-center, randomized, placebo-controlled trial. American Brain Injury Consortium Study Group. J. Neurotrauma 1999; 16: 431–44.
10.1089/neu.1999.16.431
CAS PubMed Web of Science® Google Scholar
13 Knoller N, Levi L, Shoshan I et al. Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. Crit. Care Med. 2002; 30: 548–54.
10.1097/00003246-200203000-00009
CAS PubMed Web of Science® Google Scholar
14 Teasdale GM, Pettigrew LE, Wilson JT, Murray G, Jennett B. Analyzing outcome of treatment of severe head injury: a review and update on advancing the use of the Glasgow Outcome Scale. J. Neurotrauma 1998; 15: 587–97.
10.1089/neu.1998.15.587
CAS PubMed Web of Science® Google Scholar
15 Marion DW, Penrod LE, Kelsey SF et al. Treatment of traumatic brain injury with moderate hypothermia. N. Engl. J. Med. 1997; 336: 540–46.
10.1056/NEJM199702203360803
CAS PubMed Web of Science® Google Scholar
16 Alderson P, Gadkary C, Signorini DF. Therapeutic hypothermia for head injury. Cochrane Database Syst. Rev. 2004; (4): CD001048.
10.1002/14651858.CD001048.pub2
PubMed Google Scholar
17 Adelson PD, Ragheb J, Kanev P et al. Phase II clinical trial of moderate hypothermia after severe traumatic brain injury in children. Neurosurgery 2005; 56: 740–54.
10.1227/01.NEU.0000156471.50726.26
PubMed Web of Science® Google Scholar
18 Knoblach SM, Alroy DA, Nikolaeva M, Cernak I, Stoica BA, Faden AI. Caspase inhibitor z-DEVD-fmk attenuates calpain and necrotic cell death in vitro and after traumatic brain injury. J. Cereb. Blood Flow Metab. 2004; 24: 1119–32.
10.1097/01.WCB.0000138664.17682.32
CAS PubMed Web of Science® Google Scholar
19 Hortobagyi T, Gorlach C, Benyo Z et al. Inhibition of neuronal nitric oxide synthase-mediated activation of poly (ADP-ribose) polymerase in traumatic brain injury: neuroprotection by 3-aminobenzamide. Neuroscience 2003; 121: 983–90.
10.1016/S0306-4522(03)00482-2
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume9, Issue4

November 2005

Pages 122-125

Cerebral protection in traumatic brain injury

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Cerebral protection in traumatic brain injury

Abstract

References

Citing Literature

References

Related

Information